| Symbol | TVTX |
|---|---|
| Name | TRAVERE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3611 VALLEY CENTRE DRIVE,SUITE 300, SAN DIEGO, California, 92130, United States |
| Telephone | +1 888 969-7879 |
| Fax | — |
| — | |
| Website | https://www.travere.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001438533 |
| Description | Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. Additional info from NASDAQ: |
2026-08-14 11:29
New Form SCHEDULE 13G/A - Travere Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003621 <b>Size:</b> 10 KB
Read more
2026-08-12 21:00
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-08-12 14:29
New Form SCHEDULE 13G - Travere Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000070858-26-000437 <b>Size:</b> 171 KB
Read more
2026-08-07 12:03
New Form SCHEDULE 13G - Travere Therapeutics, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000546 <b>Size:</b> 8 KB
Read more
2026-07-27 12:50
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Read more
2026-06-22 20:37
Inrig Jula 🔴 sold 468 shares of Travere Therapeutics, Inc. (TVTX) Transaction Date: Jun 22, 2026 | Filing ID: 000007
Read more
2026-06-17 17:33
New Form S-8 - Travere Therapeutics, Inc. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001438533-26-000052 <b>Size:</b> 310 KB
Read more
2026-06-16 20:46
Coughlin Timothy 🟡 adjusted position in 10.0K shares (1 derivative) of Travere Therapeutics, Inc. (TVTX) at $50.07 ($1.0M) Transaction Date: Jun 12, 2026 | Filing ID: 000010
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07224776 | Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Pro… | Phase1 | Proteinuric Renal Disease | Recruiting | 2026-07-10 | 2028-12-01 | ClinicalTrials.gov |
| NCT07219121 | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Gl… | Phase4 | Proteinuria | Active_Not_Recruiting | 2025-10-07 | 2027-05-01 | ClinicalTrials.gov |
| NCT06431893 | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegt… | Phase3 | Homocystinuria | Enrolling_By_Invitation | 2024-04-30 | 2030-08-01 | ClinicalTrials.gov |
| NCT06548022 | Rare Group Problem Management Plus | Na | Anxiety | Completed | 2024-02-05 | 2025-11-30 | ClinicalTrials.gov |
| NCT06247085 | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Place… | Phase3 | Homocystinuria | Recruiting | 2023-12-28 | 2027-09-01 | ClinicalTrials.gov |
| NCT05856760 | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT… | Phase2 | Immunoglobulin A Nephropathy | Completed | 2023-05-19 | 2024-10-25 | ClinicalTrials.gov |
| NCT05630612 | ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) | Phase2 | ANCA Associated Vasculitis | Active_Not_Recruiting | 2022-12-08 | 2027-09-01 | ClinicalTrials.gov |
| NCT05200871 | Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immuno… | — | Focal Segmental Glomerulosclerosis | Completed | 2022-02-05 | 2023-10-31 | ClinicalTrials.gov |
| NCT05003986 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Phase2 | Focal Segmental Glomerulosclerosis | Recruiting | 2021-08-12 | 2027-04-12 | ClinicalTrials.gov |
| NCT04663204 | A Study of the Safety and Activity of Sparsentan for the Treatment of Patients … | Phase2 | Immunoglobulin A Nephropathy | Recruiting | 2020-12-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT05562362 | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | Phase1 | Healthy Subjects | Completed | 2020-06-18 | 2020-11-12 | ClinicalTrials.gov |
| NCT03406611 | Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (… | Phase1 | Homocystinuria | Recruiting | 2019-01-22 | 2027-07-01 | ClinicalTrials.gov |
| NCT03762850 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients Wit… | Phase3 | Immunoglobulin A Nephropathy | Active_Not_Recruiting | 2018-12-11 | 2026-07-01 | ClinicalTrials.gov |
| NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis… | Phase3 | Focal Segmental Glomerulosclerosis | Completed | 2018-04-17 | 2026-03-19 | ClinicalTrials.gov |
| NCT03041116 | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants | Phase3 | Pantothenate Kinase-Associated Neurodegeneration | Terminated | 2017-07-17 | 2019-12-30 | ClinicalTrials.gov |
| NCT02998710 | Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase D… | — | Homocystinuria Due to CBS Deficiency | Recruiting | 2017-01-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT02638220 | Cerebrotendinous Xanthomatosis (CTX) Prevalence Study | — | Cerebrotendinous Xanthomatosis (CTX) | Completed | 2015-09-01 | 2021-02-19 | ClinicalTrials.gov |
| NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in F… | Phase2 | Focal Segmental Glomerulosclerosis | Completed | 2014-03-01 | 2024-03-25 | ClinicalTrials.gov |
Total clinical trials: 18
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Homocystinuria | RECRUITING | NCT03406611 |
| Pegtibatinase | Other | Phase PHASE1 | Homocystinuria | RECRUITING | NCT03406611 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | RECRUITING | NCT07224776 |
| Sparsentan | Other | Phase PHASE4 | Proteinuria | ACTIVE_NOT_RECRUITING | NCT07219121 |
| Sparsentan | Other | Phase PHASE2 | Immunoglobulin A Nephropathy | RECRUITING | NCT04663204 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | ENROLLING_BY_INVITATION | NCT06431893 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | RECRUITING | NCT06247085 |
| RE-021, sparsentan | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05562362 |
| Placebo | Other | Phase PHASE3 | Pantothenate Kinase-Associated Neurodegeneration | TERMINATED | NCT03041116 |
| Fosmetpantotenate | Other | Phase PHASE3 | Pantothenate Kinase-Associated Neurodegeneration | TERMINATED | NCT03041116 |
| Placebo | Other | Phase PHASE1 | Homocystinuria | ACTIVE_NOT_RECRUITING | NCT03406611 |
| Pegtibatinase | Other | Phase PHASE1 | Homocystinuria | ACTIVE_NOT_RECRUITING | NCT03406611 |
| Sparsentan | Other | Phase PHASE2 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT04663204 |
| Placebo | Other | Phase PHASE3 | Homocystinuria | ACTIVE_NOT_RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | ACTIVE_NOT_RECRUITING | NCT06247085 |
| Pegtibatinase | Other | Phase PHASE3 | Homocystinuria | ENROLLING_BY_INVITATION | NCT06431893 |
| Irbesartan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT01613118 |
| RE-021 (Sparsentan) | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT01613118 |
| Sparsentan | Other | Phase PHASE2 | ANCA Associated Vasculitis | ACTIVE_NOT_RECRUITING | NCT05630612 |
| Sparsentan | Other | Phase PHASE2 | Immunoglobulin A Nephropathy | COMPLETED | NCT05856760 |
| Sparsentan | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT05003986 |
| No sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| sparsentan | Other | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| Sparsentan | Other | Phase PHASE4 | Proteinuria | RECRUITING | NCT07219121 |
| Rare Group Problem Management Plus | Other | Approved | Anxiety | COMPLETED | NCT06548022 |
| Irbesartan | Other | Phase PHASE3 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT03493685 |
| sparsentan | Other | Phase PHASE3 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT03493685 |
| Dapagliflozin | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT03762850 |
| irbesartan | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT03762850 |
| sparsentan | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT03762850 |
| Irbesartan | Other | Phase PHASE3 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT03493685 |
| sparsentan | Other | Phase PHASE3 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT03493685 |
| No sparsentan | DRUG | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| Rare Group Problem Management Plus | BEHAVIORAL | Approved | Anxiety | COMPLETED | NCT06548022 |
| RE-021, sparsentan | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05562362 |
| Sparsentan | DRUG | Phase PHASE4 | Proteinuria | RECRUITING | NCT07219121 |
| Dapagliflozin | DRUG | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT03762850 |
| irbesartan | DRUG | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT03762850 |
| sparsentan | DRUG | Phase PHASE1 | Proteinuric Renal Disease | NOT_YET_RECRUITING | NCT07224776 |
| Pegtibatinase | DRUG | Phase PHASE3 | Homocystinuria | ENROLLING_BY_INVITATION | NCT06431893 |
| Placebo | OTHER | Phase PHASE3 | Homocystinuria | ACTIVE_NOT_RECRUITING | NCT06247085 |
| Fosmetpantotenate | DRUG | Phase PHASE3 | Pantothenate Kinase-Associated Neurodegeneration | TERMINATED | NCT03041116 |
| Irbesartan | DRUG | Phase PHASE3 | Focal Segmental Glomerulosclerosis | ACTIVE_NOT_RECRUITING | NCT03493685 |
| RE-021 (Sparsentan) | DRUG | Phase PHASE2 | Focal Segmental Glomerulosclerosis | COMPLETED | NCT01613118 |
Total products: 92